DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 7.964,607 B2 Verhoest Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 7.964,607 B2 Verhoest Et Al US007964607B2 (12) United States Patent (10) Patent No.: US 7.964,607 B2 Verhoest et al. (45) Date of Patent: Jun. 21, 2011 (54) PYRAZOLO3,4-DIPYRIMIDINE FOREIGN PATENT DOCUMENTS COMPOUNDS EP 1460.077 9, 2004 WO 02085904 10, 2002 (75) Inventors: Patrick Robert Verhoest, Old Lyme, CT WO 2004037176 5, 2004 (US); Caroline Proulx-Lafrance, Ledyard, CT (US) OTHER PUBLICATIONS Wunder et al., Mol. Pharmacol., vol. 28, No. 6, (2005), pp. 1776 (73) Assignee: Pfizer Inc., New York, NY (US) 1781. van der Staay et al., Neuropharmacology, vol. 55 (2008), pp. 908 (*) Notice: Subject to any disclaimer, the term of this 918. patent is extended or adjusted under 35 U.S.C. 154(b) by 562 days. Primary Examiner — Susanna Moore (74) Attorney, Agent, or Firm — Jennifer A. Kispert; (21) Appl. No.: 12/118,062 Michael Herman (22) Filed: May 9, 2008 (57) ABSTRACT (65) Prior Publication Data The invention provides PDE9-inhibiting compounds of For US 2009/OO3OOO3 A1 Jan. 29, 2009 mula (I), Related U.S. Application Data (I) O (60) Provisional application No. 60/917.333, filed on May R 11, 2007. H N N N (51) Int. Cl. R3 N CO7D 487/04 (2006.01) WS M A 6LX3/59 (2006.01) s' N N A61 P 25/28 (2006.01) R N (52) U.S. Cl. ..................................... 514/262.1; 54.4/262 / (58) Field of Classification Search .................. 544/262: R 51.4/262.1 See application file for complete search history. and pharmaceutically acceptable salts thereof, wherein R. R. (56) References Cited RandR areas defined herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in U.S. PATENT DOCUMENTS treating neurodegenerative and cognitive disorders, such as 2003. O139427 A1 7/2003 Castelhano et al. ....... 514,2611 Alzheimer's disease and Schizophrenia, are also provided. 2004/0176361 A1 9/2004 Fujio et al. ................. 514,224.2 2004/0259870 Al 12/2004 Feng et al. ................. 514,229.2 13 Claims, No Drawings US 7,964,607 B2 1. 2 PYRAZOLO3,4-DIPYRIMIDINE 47:1081-1092 (2004). Inhibition of PDE9 has been shown to COMPOUNDS increase LTP. Hendrix, BMC Pharmacol., 5(Supp. 1):55 (2005). RELATED APPLICATION Accordingly, there is a need for PDE9 inhibitors that are effective in treating conditions that may be regulated or nor This application claims the benefit under 35 U.S.C. S 119 malized by inhibition of PDE9. (e) of U.S. provisional application Ser. No. 60/917.333, filed May 11, 2007. SUMMARY OF THE INVENTION FIELD OF THE INVENTION 10 The present invention is directed to compounds of Formula (I), This invention relates to a series of novel compounds that are selective inhibitors of phosphodiesterase type 9 (“PDE9). More particularly, the invention relates to pyra (I) Zolo3,4-dipyrimidinone compounds for use in the treatment 15 O R and prevention of neurodegenerative diseases and other dis H eases and disorders influenced by modulation of PDE9. n N N BACKGROUND OF THE INVENTION R3 WSls M N s N N Cyclic nucleotides cyclic guanosine monophosphate R N (cGMP) and cyclic adenosine monophosphate (cAMP) are / important second messengers and thus are central to the con R trol and regulation of a multitude of cellular events, both physiological and pathophysiological, in a wide variety of 25 Organs. and pharmaceutically acceptable salts thereof, wherein R. R. Cyclic GMP is formed from GTP by the catalytic reaction R, and R are as defined herein. of guanylyl cyclase (GC), which is activated by nitric oxide The present invention is also directed to compositions con (NO). Cyclic GMP in turn activates cGMP-dependent protein taining a compound of Formula (I), or a pharmaceutically kinases (cGK), which mediate localized and global signaling. 30 acceptable salt thereof, and a pharmaceutically acceptable A variety of physiological processes in the cardiovascular, vehicle, carrier or diluent, and optionally further comprising nervous and immune systems are controlled by the a second pharmaceutical agent. NO/cGMP pathway, including ion channel conductance, gly The present invention is further directed to a method of cogenolysis, cellular apoptosis, and Smooth muscle relax inhibiting PDE9 in a mammal in need of such inhibition, ation. In blood vessels, relaxation of vascular Smooth muscles 35 comprising the step of administering to the mammala PDE9 leads to vasodilation and increased blood flow. inhibiting amount of a) a compound of Formula I, or a phar The phosphodiesterase (PDE) enzyme family hydrolyses maceutically acceptable salt thereof, or b) a pharmaceutical cGMP and cAMP. The PDE9 enzyme has been identified as a composition comprising a compound of Formula I, or a phar novel member of the PDE enzyme family that selectively maceutically acceptable salt thereof, and a pharmaceutically hydrolyses cGMP over cAMP. See Fisher et al., J. Biol. 40 Chem., 273 (25), 15559-15564 (1998). PDE9 has been found acceptable vehicle, carrier or diluent. to be present in a variety of human tissues, namely the testes, The present invention is further directed to a method of brain, Small intestine, skeletal muscle, heart, lung, thymus treating a neurodegenerative disease in a mammal in need of and spleen, as well as in Smooth muscle cells within the Such treatment, comprising the step of administering to the human vasculature of a variety of tissues. 45 mammalatherapeutically effective amount of a compound of Recent studies have directly implicated dysfunction of Formula I, or a pharmaceutically acceptable salt thereof. NO/cGMP/cGK signaling in Alzheimer's disease. For The present invention is further directed to a method of example, disruption of Long Term Potentiation (LTP), a promoting neurorestoration in a mammal in need of Such physiological correlate of learning and memory, by amy neurorestoration, comprising the step of administering to the loid-fi peptide was shown to result from a malfunction of 50 mammalatherapeutically effective amount of a compound of NO/cGMP signaling. Puzzo et al., J. Neurosci., 25(29):6887 Formula I, or a pharmaceutically acceptable salt thereof. 6897 (2005). Moreover, in rats showing deficits in memory The present invention is still further directed to a method of tasks due to depletion in forebrain acetylcholinesterase improving cognitive deficits and treating cognitive impair (which is associated with Alzheimer's disease), administra ment in a mammal in need of such improvement or treatment, tion of a nitric oxide mimetic increased GC activity and 55 comprising the step of administering to the mammal athera reversed the cognitive deficits in memory tasks. Bennett et al., peutically effective amount of a compound of Formula I, or a Neuropsychopharmacology, 32:505-513 (2007). It is there pharmaceutically acceptable salt thereof. fore believed that therapeutic agents capable of enhancing the With the foregoing and other advantages and features of the GC/NO/cGMP/cGK signaling cascade may be useful as a invention that will become hereinafter apparent, the nature of new approach to the treatment of Alzheimer's disease and 60 the invention may be more clearly understood by reference to other neurodegenerative disorders. the following detailed description of the invention and the By reducing or preventing the hydrolysis of c(GMP by appended claims. PDE9, PDE9 inhibitors elevate the intracellular level of cGMP, thus enhancing or prolonging its effects. It has been DETAILED DESCRIPTION OF THE INVENTION found that an increase incGMP concentration in rats leads to 65 improvement in learning and memory in Social and object The present invention comprises novel selective PDE9 recognition tests. See, e.g., Boess et al., Neuropharmacology, inhibitors of Formula (I), US 7,964,607 B2 15 16 The term “aryl' is also intended to include the partially hydro 3-bipyrazinyl), pyridopyridinyl, pyrrolopyrazolyl, dihydro genated derivatives of Such ring systems, e.g. 1.2.3,4-tetrahy pyrrolopyrazolyl (e.g. dihydropyrrolo 1.2-bipyrazolyl), dronaphthyl. quinazolinyl (also known as “1,3-benzodiazinyl'), quinolinyl The term “aryloxy' denotes an aryl radical bonded to an (also known as "1-benzazinyl), isoquinolinyl (also known as oxygen atom that is attached to a core structure. Such as 5 “2-benzazinyl'), quinolizinyl, quinolyl, isoquinolyl, quinox benzyloxy. alinyl, dithianaphthalenyl, thienofuranyl (e.g. thieno3.2-b The term "cycloalkyl denotes a saturated monocyclic or furanyl), and the like. bicyclic cycloalkyl group. Examples of cycloalkyl groups Examples of 3-fused ring heteroaryls include acridinyl, include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, diazaanthryl, triaZaphenanthrene, carbazolyl, carbolinyl, cycloheptyl, cyclooctyl, and the like. 10 furocinnolinyl, perimidinyl, phenanthridinyl, phenanthroli The term “halogen' or “halo represents chlorine, bro nyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazi mine, fluorine and iodine atoms and radicals. The term “haloalkyl refers to an alkyl or cycloalkyl sub nyl, thianthrenyl, Xanthenyl, and the like. stituent wherein at least one hydrogen radical is replaced with The term "heterocycloalkyl denotes a saturated monocy a halogen radical. Where more than one hydrogen is replaced 15 clic or polycyclic cycloalkyl group, in which at least one of with halogen, the halogens may be the same or different. the carbon atoms is replaced with a heteroatom such as nitro Examples of haloalkyl radicals include trifluoromethyl, 2.2, gen, oxygen or Sulfur. If the heterocycle contains more than 2-trifluoroethyl, 4.4,4-trifluorobutyl, 4.4-difluorocyclohexyl, one heteroatom, the heteroatoms may be the same or differ chloromethyl, dichloromethyl, trichloromethyl, 1-bromoet ent. The heterocycloalkyl radicals may be bonded via a car hyl, and the like. bon atom or a heteroatom. Examples of heterocycloalkyl The term “haloalkoxy” refers to an alkoxy radical in which groups include aZetidinyl, dioxacyclohexyl, 1,3-dioxolanyl. at least one hydrogen radical is replaced with a halogen radi imidazolidinyl, morpholinyl, piperazinyl, piperidinyl, pyra cal. Where more than one hydrogen is replaced with halogen, Zolidinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl. the halogens may be the same or different. Examples of tetrahydrothiopyranyl, thiazanyl, and the like.
Load more

Recommended publications
  • Phosphodiesterase-5 Inhibitors and the Heart: Heart: First Published As 10.1136/Heartjnl-2017-312865 on 8 March 2018
    Heart Online First, published on March 8, 2018 as 10.1136/heartjnl-2017-312865 Review Phosphodiesterase-5 inhibitors and the heart: Heart: first published as 10.1136/heartjnl-2017-312865 on 8 March 2018. Downloaded from compound cardioprotection? David Charles Hutchings, Simon George Anderson, Jessica L Caldwell, Andrew W Trafford Unit of Cardiac Physiology, ABSTRACT recently reported that PDE5i use in patients with Division of Cardiovascular Novel cardioprotective agents are needed in both type 2 diabetes (T2DM) and high cardiovascular Sciences, School of Medical risk was associated with reduced mortality.6 The Sciences, Faculty of Biology, heart failure (HF) and myocardial infarction. Increasing Medicine and Health, The evidence from cellular studies and animal models effect was stronger in patients with prior MI and University of Manchester, indicate protective effects of phosphodiesterase-5 was associated with reduced incidence of new MI, Manchester Academic Health (PDE5) inhibitors, drugs usually reserved as treatments of raising the possibility that PDE5is could prevent Science Centre, Manchester, UK erectile dysfunction and pulmonary arterial hypertension. both complications post-MI and future cardio- PDE5 inhibitors have been shown to improve vascular events. Subsequent similar findings were Correspondence to observed in a post-MI cohort showing PDE5i use Dr David Charles Hutchings, contractile function in systolic HF, regress left ventricular Institute of Cardiovascular hypertrophy, reduce myocardial infarct size and suppress was accompanied with reduced mortality and HF 7 Sciences, The University of ischaemia-induced ventricular arrhythmias. Underpinning hospitalisation. Potential for confounding in these Manchester, Manchester, M13 these actions are complex but increasingly understood observational studies is high, however, and data 9NT, UK; david.
    [Show full text]
  • Phosphodiesterase (PDE)
    Phosphodiesterase (PDE) Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules. www.MedChemExpress.com 1 Phosphodiesterase (PDE) Inhibitors, Activators & Modulators (+)-Medioresinol Di-O-β-D-glucopyranoside (R)-(-)-Rolipram Cat. No.: HY-N8209 ((R)-Rolipram; (-)-Rolipram) Cat. No.: HY-16900A (+)-Medioresinol Di-O-β-D-glucopyranoside is a (R)-(-)-Rolipram is the R-enantiomer of Rolipram. lignan glucoside with strong inhibitory activity Rolipram is a selective inhibitor of of 3', 5'-cyclic monophosphate (cyclic AMP) phosphodiesterases PDE4 with IC50 of 3 nM, 130 nM phosphodiesterase. and 240 nM for PDE4A, PDE4B, and PDE4D, respectively. Purity: >98% Purity: 99.91% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 10 mg, 50 mg (R)-DNMDP (S)-(+)-Rolipram Cat. No.: HY-122751 ((+)-Rolipram; (S)-Rolipram) Cat. No.: HY-B0392 (R)-DNMDP is a potent and selective cancer cell (S)-(+)-Rolipram ((+)-Rolipram) is a cyclic cytotoxic agent. (R)-DNMDP, the R-form of DNMDP, AMP(cAMP)-specific phosphodiesterase (PDE) binds PDE3A directly.
    [Show full text]
  • (Medical and Mechanical) Treatment of Erectile Dysfunction
    130 SOP Conservative (Medical and Mechanical) Treatment of Erectile Dysfunctionjsm_12023 130..171 Hartmut Porst, MD,* Arthur Burnett, MD, MBA, FACS,† Gerald Brock, MD, FRCSC,‡ Hussein Ghanem, MD,§ Francois Giuliano, MD,¶ Sidney Glina, MD,** Wayne Hellstrom, MD, FACS,†† Antonio Martin-Morales, MD,‡‡ Andrea Salonia, MD,§§ Ira Sharlip, MD,¶¶ and the ISSM Standards Committee for Sexual Medicine *Private Urological/Andrological Practice, Hamburg, Germany; †The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, MD, USA; ‡Division of Urology, University of Western, ON, Canada; §Sexology & STDs, Cairo University, Cairo, Egypt; ¶Neuro-Urology-Andrology Unit, Department of Physical Medicine and Rehabilitation, Raymond Poincaré Hospital, Garches, France; **Instituto H.Ellis, São Paulo, Brazil; ††Department of Urology, Section of Andrology and Male Infertility, Tulane University School of Medicine, New Orleans, LA, USA; ‡‡Unidad Andrología, Servicio Urología Hospital, Regional Universitario Carlos Haya, Málaga, Spain; §§Department of Urology & Urological Reseach Institute (URI), Universiti Vita Saluta San Raffaele, Milan, Italy; ¶¶University of California at San Francisco, San Francisco, CA, USA DOI: 10.1111/jsm.12023 ABSTRACT Introduction. Erectile dysfunction (ED) is the most frequently treated male sexual dysfunction worldwide. ED is a chronic condition that exerts a negative impact on male self-esteem and nearly all life domains including interper- sonal, family, and business relationships. Aim. The aim of this study
    [Show full text]
  • Can PDE Inhibition Improve Cognition? : Translational Insights
    Can PDE inhibition improve cognition? : Translational insights Citation for published version (APA): Reneerkens, O. A. H. (2013). Can PDE inhibition improve cognition? : Translational insights. Maastricht University. https://doi.org/10.26481/dis.20130418or Document status and date: Published: 01/01/2013 DOI: 10.26481/dis.20130418or Document Version: Publisher's PDF, also known as Version of record Please check the document version of this publication: • A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website. • The final author version and the galley proof are versions of the publication after peer review. • The final published version features the final layout of the paper including the volume, issue and page numbers. Link to publication General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal. If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above, please follow below link for the End User Agreement: www.umlib.nl/taverne-license Take down policy If you believe that this document breaches copyright please contact us at: [email protected] providing details and we will investigate your claim.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Phosphodiesterase Type 5 Inhibitors - a Priority Direction for the Treatment of Erectile Dysfunction of Various Origins
    Turkish Journal of Physiotherapy and Rehabilitation; 32(3) ISSN 2651-4451 | e-ISSN 2651-446X PHOSPHODIESTERASE TYPE 5 INHIBITORS - A PRIORITY DIRECTION FOR THE TREATMENT OF ERECTILE DYSFUNCTION OF VARIOUS ORIGINS Gafarov R.R.1, Bobokulov N.A.1, Batirov B.A.1, Muradov S.S.2 1 Samarkand State Medical Institute, 2 Sogda Medical Centre Erectile dysfunction (ED) is a condition in which a man is unable to achieve and maintain an erection to a degree sufficient for successful intercourse. ED is a serious problem affecting both the psychosocial state of the man and his partner [1]. In the ED development, the role of bad habits is great, for example, among smoking men it occurs 20% more often than among nonsmokers [2,3]. ED is associated with various comorbid conditions such as hypertension, hyperlipidemia, metabolic syndrome, lower urinary tract symptoms (LUTS) or benign prostatic hyperplasia (BPH), cardiovascular disease, psychological factors, diabetes mellitus, post-radical prostatectomy, antidepressant medication and antihypertensive drugs, etc. (Table 1). Table 1. Pathophysiology of ED [4]. Vasculogenic Recreational habits (i.e., cigarette smoking) Lack of regular physical exercise Obesity Cardiovascular diseases (e.g. hypertension, coronary artery disease, peripheral vasculopathy) Type 1 and 2 diabetes mellitus; hyperlipidaemia; metabolic syndrome; hyperhomocysteinemia Major pelvic surgery (e.g., radical prostatectomy) or radiotherapy (pelvis or retroperitoneum) Neurogenic Central causes Degenerative disorders (e.g., multiple sclerosis,
    [Show full text]
  • Comparative Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction in Diabetic Men: a Bayesian Netw
    World Journal of Urology (2019) 37:1061–1074 https://doi.org/10.1007/s00345-018-2583-1 REVIEW Comparative efcacy and safety of phosphodiesterase type 5 inhibitors for erectile dysfunction in diabetic men: a Bayesian network meta‑analysis of randomized controlled trials Xinyang Liao1 · Shi Qiu1 · Yige Bao1 · Wanyu Wang2 · Lu Yang1 · Qiang Wei1 Received: 9 September 2018 / Accepted: 26 November 2018 / Published online: 6 December 2018 © Springer-Verlag GmbH Germany, part of Springer Nature 2018 Abstract Purpose To compare the efcacy and safety profles of diferent phosphodiesterase-5 inhibitors (PDE5Is) administrations for erectile dysfunction (ED) in diabetic men, including on-demand (PRN) and regular regimens (OAD). Materials and methods Searches were carried out in four electronic databases: PubMed (until April 17th, 2017); Scopus (until April 17th, 2017); Embase (until April 17th, 2017); and Cochrane (until April 18th, 2017). The outcomes for this study are as follows: (1) Global Assessment Question (GAQ) positive response rate; (2) changes from baseline to the end of the study in Erectile Function Domain of International Index of Erectile Function (IIEF-EF); and (3) treatment-related adverse events (TRAEs). The comparative efects of PDE5I regimens were analyzed with random-efect models in a Bayes- ian Framework using the GeMTC R package. Results We identifed 1056 records, of which 15 randomized trials with 5274 patients were included. The included stud- ies covered eight kinds of PDE5I administration: avanafl PRN; mirodenafl PRN; sildenafl PRN; tadalafl PRN; tadalafl OAD; udenafl PRN; udenafl OAD; vardenafl PRN; and placebo. In surface under the cumulative ranking curve analysis, vardenafl PRN ranked frst, third and frst, and mirodenafl PRN ranked second, frst and second in GAQ, IIEF-EF, and TRAEs, respectively.
    [Show full text]
  • Phosphodiesterase 5 Inhibitors for the Treatment of Erectile Dysfunction: a Trade-Off Network Meta-Analysis
    EURURO-6137; No. of Pages 7 E U R O P E A N U R O L O G Y X X X ( 2 0 1 5 ) X X X – X X X ava ilable at www.sciencedirect.com journa l homepage: www.europeanurology.com Platinum Priority – Review – Sexual Medicine Editorial by XXX on pp. x–y of this issue Phosphodiesterase 5 Inhibitors for the Treatment of Erectile Dysfunction: A Trade-off Network Meta-analysis a,y a,y a,b,c d e Liang Chen , Sergej E.L. Staubli , Marc P. Schneider , Alfons G. Kessels , Sandra Ivic , e a, Lucas M. Bachmann , Thomas M. Kessler * a b Neuro-Urology, Spinal Cord Injury Center & Research, University of Zu¨rich, Balgrist University Hospital, Zu¨rich, Switzerland; Brain Research Institute, c University of Zu¨rich, Zu¨rich, Switzerland; Department of Health Sciences and Technology, Swiss Federal Institute of Technology Zu¨rich, Zu¨rich, Switzerland; d e Department of Anesthesiology and Pain Medicine, Maastricht University Medical Center, Maastricht, The Netherlands; Medignition Research Consultants, Zu¨rich, Switzerland Article info Abstract Article history: Context: Erectile dysfunction (ED) is a major health care problem worldwide and phosphodiesterase 5 inhibitors (PDE5Is) are the pharmacological treatment of choice. Accepted March 15, 2015 However, the optimal PDE5I for ED treatment is not known. Objective: To investigate trade-offs between efficacy and adverse events for various Keywords: PDE5Is in treating ED. Phosphodiesterase 5 inhibitors Evidence acquisition: A review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement. Medline, Scopus, reference Erectile dysfunction lists of relevant articles, and systematic reviews were searched.
    [Show full text]
  • Udenafil, a Phosphodiesterase 5 Inhibitor, Reduces Body Weight in High-Fat-Fed Mice
    pISSN: 2287-4208 / eISSN: 2287-4690 World J Mens Health 2018 January 36(1): 41-49 https://doi.org/10.5534/wjmh.17028 Original Article Udenafil, a Phosphodiesterase 5 Inhibitor, Reduces Body Weight in High-Fat-Fed Mice Seong Yul Ryu1,*, Yoon-Jung Choi2,*, So-Young Park2, Jong-Yeon Kim2, Yong-Dae Kim3, Yong-Woon Kim2 1Department of Internal Medicine, Keimyung University School of Medicine, Departments of 2Physiology and 3Otolaryngology, Yeungnam University College of Medicine, Daegu, Korea Purpose: High-fat (HF) feeding induces hypothalamic leptin resistance via the activation of toll-like receptor 4 (TLR4). TLR4 deficiency confers resistance to diet-induced obesity. Udenafil, an anti-impotence drug, inhibits TLR4 in airway epithelial cells in vitro. In this study, we evaluated whether udenafil suppressed the hypothalamic expression of TLR4 and reduced body weight. Materials and Methods: The hypothalamic expression of TLR4, phosphodiesterase 5 (PDE5), nuclear factor-κB (NF-κB), and myeloid differentiation primary response gene 88 (Myd88) was analyzed by real-time polymerase chain reaction after treating mice for 2 days with udenafil (0, 12, 120, or 600 μg/d). Furthermore, the hypothalamic expression of TLR4, pro-opiomelanocortin (POMC), and neuropeptide Y (NPY) was analyzed after 9 days’ treatment with udenafil and/or leptin. We also measured body weight and food intake following 9 days of udenafil and/or leptin treatment in control- and HF-fed mice. Results: Udenafil suppressed hypothalamic TLR4 mRNA expression dose-dependently. The changes were associated with decreased PDE5, NF-κB, and Myd88 expression. Udenafil treatment for 9 days reduced body weight and caloric intake in HF-fed mice.
    [Show full text]
  • Efficacy and Safety of Phosphodieterase-5
    Spinal Cord (2016) 54, 494–501 & 2016 International Spinal Cord Society All rights reserved 1362-4393/16 www.nature.com/sc REVIEW Efficacy and safety of phosphodieterase-5 inhibitors for treatment of erectile dysfunction secondary to spinal cord injury: a systemic review and meta-analysis D-D Jia, W-B Shuang, T Cheng, X-M Jia and M Zhang Study design: Systemic review Objective: We carried out a systematic review and meta-analysis to assess the efficacy and safety of phosphodieterase-5 (PDE5) inhibitors on erectile dysfunction (ED) secondary to spinal cord injury (SCI). Methods: A literature review was performed to identify all published randomized, double-blind, placebo-controlled trials of PDE5 inhibitors for treatment of ED secondary to SCI. The search included the following database: MEDLINE, EMBASE and the Cochrane Library. The outcomes and complications analyzed involved the Global Efficacy Question (GEQ), sexual encounter profile diary question 2 and 3 (SEP2 and SEP3) and adverse events. All statistical analysis was performed using Stata 12.0 software (Stata Corp., College Station, TX, USA). Results: Six publications were used in analysis, including six randomized controlled trials that compared PDE5 inhibitors with placebo. Compared with placebo, PDE5 inhibitors were associated with significant improvements in GEQ (OR 11.997, 95% CI 8.073–17.830, Po0.0001), SEP2 (RR 1.847, 95% CI 1.561–2.185, Po0.0001) and SEP3 (RR 2.738, 95% CI 2.084–3.598, Po0.0001). Despite significant greater incidences of some adverse events observed (headache: RR 3.717, 95% CI 2.309–5.982, Po0.0001; flushing: RR 9.281, 95% CI 2.858–30.147, Po0.0001; gastrointestinal discomfort: RR 9.064, 95% CI 2.116–38.827, P = 0.003), most adverse events were mild to moderate and transient.
    [Show full text]